CALL/VERTEX PHARMACEUTICALS/700/0.1/19.07.24 | Market Closed - Börse Stuttgart 05:23:30 2024-05-17 EDT | ||
| 0.01 EUR | 0.00% |
|
| Current month | +150.00% | ||
| 1 month | -50.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.01 | 0.00% |
| 24-05-16 | 0.01 | +233.33% |
| 24-05-15 | 0.003 | +200.00% |
| 24-05-14 | 0.001 | 0.00% |
| 24-05-13 | 0.001 | 0.00% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 05:23 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG4ULW |
| ISIN | DE000GG4ULW6 |
| Date issued | 2024-03-05 |
| Strike | 700 $ |
| Maturity | 2024-07-19 (62 Days) |
| Parity | 10 : 1 |
| Emission price | 0.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.09 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.298 € |
| Spread % | 99.33% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Warrants
- Warrant
